Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Preclinical Development: Overview01:28

Preclinical Development: Overview

5.7K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
5.7K
Clinical Trials: Overview01:11

Clinical Trials: Overview

4.5K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.5K
Drug Discovery: Overview01:26

Drug Discovery: Overview

10.9K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
10.9K
Drug Administration and Therapy Phases: Overview01:26

Drug Administration and Therapy Phases: Overview

1.1K
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
1.1K
In Vitro Drug Release Testing: Overview, Development and Validation01:10

In Vitro Drug Release Testing: Overview, Development and Validation

279
In vitro dissolution and drug release tests assess how quickly and how much of a drug is released from its dosage form into an aqueous medium under standardized laboratory conditions. These tests are essential tools in pharmaceutical development and quality assurance, offering insight into the drug's performance before clinical use.During formulation development, dissolution testing identifies incomplete or inconsistent drug release issues. It also supports decisions on selecting the optimal...
279
Drug Regulation01:25

Drug Regulation

2.7K
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
2.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Genomic characterization of multidrug-resistant Escherichia coli isolated from gills of Labeo rohita: Insight into resistome, virulence and pathogenicity.

PloS one·2026
Same author

YATSIDroid: an android malware detection framework based on artificial immune system.

Scientific reports·2026
Same author

Study of interfacial synergy in strontium-based organic framework/polyaniline/nanoporous graphene ternary composite as positive electrode for battery-supercapacitor hybrid devices.

RSC advances·2026
Same author

Palladium anchored to magnetic silica functionalized with AP groups as a novel and efficient heterogeneous catalyst for C-C coupling reactions.

Scientific reports·2026
Same author

Correction: An efficient Alzheimer's disease detection by NV classifier with BWTDL approach using MRI image.

BMC medical imaging·2026
Same author

A prospective review of transfusion practices in paediatric trauma patients at level 1 trauma centre.

Injury·2026
Same journal

Evidence for progressive neurodegeneration in iatrogenic cerebral amyloid angiopathy.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Human brain connectome profiles mediate the relationship between pathology burden and clinical phenotypes in Alzheimer's disease.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Kat5 cKO mouse replicates biological domain signatures associated with Alzheimer's disease.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Evaluation of CSF and plasma tau species as fluid surrogate candidates for tau PET in prodromal to moderate Alzheimer's disease.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Associations of self-reported obstructive sleep apnea with cognition and dementia risk in cognitively unimpaired middle-aged adults.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Inflammation profiles in Alzheimer's disease relate to cognition and neurodegeneration.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
See all related articles

Related Experiment Video

Updated: Jan 7, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

10.1K

Drug Development.

Maxine R Nelson1, Marina Kovaliov1, Priyanka Singh1

  • 1Switch Therapeutics, South San Francisco, CA, USA.

Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association
|December 26, 2025
PubMed
Summary
This summary is machine-generated.

A novel conditionally activating siRNA (CASi) effectively reduces brain Apolipoprotein E (APOE) mRNA in Alzheimer's disease (AD) models. This targeted approach spares peripheral APOE and cholesterol, offering a promising therapy for APOE*ε4 carriers.

More Related Videos

In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing
08:04

In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing

Published on: May 11, 2021

3.3K
Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells
05:45

Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells

Published on: October 10, 2025

451

Related Experiment Videos

Last Updated: Jan 7, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

10.1K
In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing
08:04

In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing

Published on: May 11, 2021

3.3K
Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells
05:45

Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells

Published on: October 10, 2025

451

Area of Science:

  • Neuroscience
  • Genetics
  • Pharmacology

Background:

  • The Apolipoprotein E (APOE)*ε4 allele is the primary genetic risk factor for late-onset Alzheimer's disease (AD).
  • Preclinical studies indicate that reducing APOE4 mRNA levels can mitigate AD pathology.
  • Developing targeted therapies for APOE*ε4 carriers with mild cognitive impairment (MCI) or AD is crucial, necessitating brain-specific APOE reduction while preserving systemic functions.

Purpose of the Study:

  • To develop and evaluate a novel, potent, conditionally activating siRNA (CASi) designed to specifically target and reduce APOE mRNA within the brain.
  • To assess the safety and efficacy of the CASi in preclinical models, focusing on brain APOE reduction without impacting peripheral APOE levels or cholesterol metabolism.

Main Methods:

  • A library of CASi molecules targeting APOE was designed and tested in induced pluripotent stem cell (iPSC)-derived astrocytes.
  • In vivo efficacy was evaluated in human APOE4 transgenic (hE4) mice across a dose range, assessing APOE mRNA and protein levels in brain regions and the liver.
  • The lead CASi candidate was further tested in nonhuman primates (NHPs) via intrathecal administration, with APOE levels measured in cerebrospinal fluid (CSF), brain tissue, and plasma.

Main Results:

  • The lead CASi molecule demonstrated high potency (<20pM) in iPSC astrocytes and achieved 60-85% APOE mRNA reduction in the hippocampus of hE4 mice at a 10nmol dose.
  • The CASi was well-tolerated in mice, with no observed APOE knockdown in the liver and no changes in peripheral cholesterol levels.
  • NHP studies showed sustained 50-75% APOE protein knockdown in CSF and significant reduction in the entorhinal cortex and hippocampus, without affecting liver or plasma APOE.

Conclusions:

  • A potent CASi targeting brain APOE was identified, demonstrating significant efficacy and a favorable safety profile with no adverse effects on liver APOE or peripheral cholesterol.
  • This CASi represents a promising therapeutic candidate for APOE*ε4 carriers with MCI/AD, particularly those who cannot tolerate current immunotherapies.